Evofem Q2 net sales up 69% to $4.2M; operating loss improves 81% to $1.4M

Evofem Biosciences, Inc.

2024-Q2 EPS reported -$0.07 revenue$7,763,000

Net product sales $4.2M (+69% YoY); net income $1.3M ($0.02/share) vs net loss $8.6M ($5.43) in prior year.
Operating expenses down 43% to $5.5M; operating loss improved 81% to $1.4M.
Acquired global rights to SOLOSEC (secnidazole) for bacterial vaginosis and trichomoniasis.
Licensed Phexxi commercial rights in Middle East to Pharma 1 Drug Store; partnered with Hello Alpha.
Received $2.0M from Aditxt related to merger; targeting late 2024 close.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.